| Bioactivity | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1]. |
| Target | Ebolaviru (EBOV) |
| Name | Atoltivimab |
| CAS | 2135632-29-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc). 2021 Aug;57(8):483-490. |